Anakinra for treating Still’s disease: Appraisal consultation document

DRAFT guidance recommends anakinra for adult-onset Still’s disease that has responded inadequately to ≥2 conventional DMARDs, & for systemic juvenile idiopathic arthritis in people age ≥8 months with a body weight of ≥10 kg that has not responded to at least 1 conventional DMARD.

Source:

National Institute for Health and Care Excellence